SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is actively trending as investors prepare for a pivotal shareholder meeting addressing proposals for increased share authorization and executive compensation, alongside the company's recent move to begin staking its significant Ethereum holdings. Community discussions are highly polarized, with long-term optimists viewing current dips as tax-loss-driven buying opportunities, while critics express significant concern over dilution, stock underperformance against Ethereum, and perceived self-serving management actions.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending after announcing a proposed business combination with Applied Digital's cloud computing division to form "ChronoScale," an AI compute platform. This strategic pivot toward AI infrastructure has ignited intense speculation among traders, with many anticipating significant upside for the low-float stock. However, a strong contingent of the community is voicing concerns about potential dilution for existing shareholders and the company's underlying financial health, creating a highly debated and volatile trading environment.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending on strong anticipation of a Department of Energy announcement regarding plutonium awards, a key catalyst for its advanced reactor fuel and accelerated deployment timelines. Community discussion is polarized, with bulls eyeing short-squeeze potential and institutional support, while critics express concern over the company's valuation, zero revenue, and insider selling. This debate underscores the broader speculative interest in nuclear energy solutions for the AI sector.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending due to upcoming regulatory decisions, including a PDUFA date for its Cushing's syndrome drug, Relacorilant, alongside recent positive data for an ovarian cancer treatment and promising survival results for an ALS therapy. The community is actively discussing the stock's significant volatility, often attributing it to short seller activity, with many anticipating a substantial rally if key approvals materialize. This biotech is at a critical juncture, with multiple high-stakes clinical and regulatory catalysts fueling intense investor interest.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending after recent shareholder approval to extend its business combination deadline, fueling discussions around its definitive agreement with The Original Fit Factory. The community is heavily focused on ESHA's exceptionally low float, positioning it as a potential sympathy play following the explosive moves seen in other SPACs like AFJK and ASPC. This sentiment highlights ESHA as a high-risk, high-reward prospect in the current "SPAC mania."

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to recent positive clinical data for Tradipitant, which shows significant potential in addressing GLP-1 induced nausea and vomiting, tapping into a massive market opportunity. This news, coupled with multiple imminent FDA decisions for other key pipeline assets, has ignited widespread community discussion about the stock's perceived undervaluation. Traders are actively monitoring these upcoming regulatory milestones and their broader implications for Vanda's future, supported by its strong cash position and existing revenue streams.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is gaining significant attention following a profitable asset sale that notably strengthened its balance sheet and sharpened its focus on core AI/edge compute. The community is actively discussing potential M&A opportunities and holds high anticipation for a substantial US Army contract where OSS is positioned as a sole-source provider. This enthusiasm is further fueled by recent strong earnings that exceeded expectations, with many viewing the company as an undervalued leader in the rapidly growing Edge AI sector.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is a focal point of discussion, with community members fiercely debating its recent price volatility. Bulls highlight the company's strong fundamentals, including a substantial contractual backlog, no debt, and projected revenue growth in the AI voice technology sector, while bears express concern over insider selling and sustained price declines. All eyes are on potential new partnerships and product developments, particularly around upcoming industry events, which many hope will serve as a catalyst for the oversold stock.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital (MARA) is generating significant discussion as it experiences new lows, fueling strong bearish sentiment centered on perceived share dilution and management's effectiveness. While many express frustration over its underperformance compared to Bitcoin and other miners, a bullish contingent believes the stock is deeply undervalued given its substantial Bitcoin holdings and a potential strategic pivot into AI/HPC data centers. The community remains sharply divided between those anticipating further declines and others predicting a major short squeeze and rebound, especially after year-end trading activities conclude.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totaling 636,914 shares, an increase of...

Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve research firms that are covering the company, MarketBeat reports. One...

Pharvaris (NASDAQ:PHVS) Shares Down 6.9% - Time to Sell?

Pharvaris (NASDAQ:PHVS) Shares Down 6.9% - Time to Sell...

Pharvaris N.V. $PHVS Shares Bought by TFG Asset Management GP Ltd

TFG Asset Management GP Ltd raised its position in shares of Pharvaris N.V. (NASDAQ:PHVS - Free Report) by 48.1% in the 2nd quarter, according to the company in its most recent disclosure with the...

Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Pharvaris from a "hold" rating to a "sell" rating in a report on Saturday...

Pharvaris (NASDAQ:PHVS) Given New $30.00 Price Target at Bank of America

Bank of America increased their price objective on shares of Pharvaris from $27.00 to $30.00 and gave the company a "neutral" rating in a research note on Thursday...

Pharvaris (NASDAQ:PHVS) Given "Buy" Rating at HC Wainwright

HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Pharvaris in a research report on Wednesday...

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.

Pharvaris (NASDAQ:PHVS) Sees Large Volume Increase - Should You Buy?

Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume - Here's What Happened...

<ul class="summary-bullets"><li>Pharvaris shares jumped in early Wednesday trading after the company reported positive Phase 3 data for its oral HAE drug deucrictibant.</li><li>Results will be used to support regulatory approval filings expected in early 2026.</li><li>The drug is positioned as an oral alternative to current injectable HAE therapies, which many patients find difficult to use.</li></ul>Shares of Pharvaris (PHVS) rose in early morning trade on Wednesday after the company reported positive Phase 3 results for its oral drug deucrictibant, aimed at treating hereditary angioedema (HAE).HAE is a rare condition that causes sudden, severe swelling attacks. The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks. The data will support marketing approval filings in early 2026.<a href="https://stocktwits.com/symbol/PHVS/sentiment">PHVS’ stock</a> rose as much as 20% in pre-market trade and was among the top trending tickers on Stocktwits. Retail sentiment around the company on the platform trended in ‘extremely bullish’ territory, accompanied by chatter at ‘extremely high’ volumes.<h2 class="st-heading-2">RAPIDe-3 Study Results</h2>The global RAPIDe-3 trial tested deucrictibant against a placebo in 134 patients across 24 countries, including adolescents and adults with different forms of HAE. The drug, taken as a 20 mg capsule, was designed for on-demand use during attacks.The results showed that the drug worked quickly and effectively. The company said patients reported initial symptom relief in just about 1.3 hours, compared with more than 12 hours for placebo. Full symptom resolution occurred in under 12 hours, compared with over a day in the placebo group. Most attacks were managed with a single capsule, and 93% of patients didn’t need extra medication.Currently, most effective HAE treatments are injections, which many patients find inconvenient. Pharvaris is working on pills that block a pathway called the bradykinin B2 receptor — the same pathway targeted by injectable drugs — to offer an easier alternative.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-climbs-above-93-000-wiping-out-over-400-million-in-shorts-bets/cLIXFLUREKy">Bitcoin Climbs Above $93,000, Wiping Out Over $400 Million In Short Bets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stocks, shares background - stock photo (representative image courtesy of Sean Gladwell via Getty Images)

PHVS Stock Jumps After Phase 3 Trial Shows Rapid Symptom Relief For Oral HAE Treatment 

The RAPIDe-3 Phase 3 study is Pharvaris’ first trial for on-demand treatment of HAE attacks.

Equity

Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.

PHVS
Pharvaris NV

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PHVS News

PHVSPharvaris NV